Enovis CORP
About Enovis CORP
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.2B
- Net income
- -$1.2B
- Total assets
- $3.8B
- Market cap
- $1.4B
- Gross margin
- 59.8%
- Operating margin
- -50.0%
- Net margin
- -52.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2B
- Cost of revenue
- $902.8M
- Gross profit
- $1.3B
- Operating expenses
- $2.5B
- Operating income
- -$1.1B
- Income tax
- $22.3M
- Net income
- -$1.2B
- EPS (basic)
- $-20.75
- EPS (diluted)
- $-20.75
Balance sheet
- Total assets
- $3.8B
- Current assets
- $1.2B
- Total liabilities
- $2.3B
- Current liabilities
- $598.5M
- Shareholders’ equity
- $1.5B
Cash flow
- Operating cash flow
- $217.3M
- Investing cash flow
- -$179.4M
- Financing cash flow
- -$52.4M
- Net cash flow
- -$14.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-20.75
- Shares outstanding
- 57.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 8, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.2B in FY2025.
- Revenue grew 44% from FY2022 to FY2025.
- Gross margin of 59.8%, net margin -52.7%.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Enovis CORP.
Write a review
News about Enovis CORP
News & sentiment via Polygon.io
